OGX-011 , OGX-427 and OGX-225 utilize second-generation antisense technology , licensed from Isis Pharmaceuticals ( NASDAQ : ISIS ) , to target and inhibit production of specific proteins which OncoGenex believes are important in tumor progression and treatment resistance .